secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2022-11-29T23:59:59+00:00
Accession:  0001619856-22-000029
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Bio receives RMAT and Fast Track designations from FDA for CB-010 CAR-T therapy
--------------------------------------------------------------------------------

- FDA grants RMAT for relapsed/refractory large B cell lymphoma (LBCL) and Fast Track for r/r B-NHL for CB-010.
- CB-010 is first allogeneic anti-CD19 CAR-T with PD-1 knockout in clinic.
- In ANTLER Phase 1 trial at dose level 1: 6/6 patients (100%) achieved CR, 3/6 (50%) maintained CR at 6 months.
- Designations offer expedited development benefits: Priority Review, Rolling Review, Accelerated Approval eligibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985622000029/0001619856-22-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985622000029/crbu-20221129.htm
  HTML page:      https://secwatch.observer/filing/0001619856-22-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer